Zhejiang Zuoli Pharmaceutical Co., Ltd. has been ranked 23rd among 36 pharmaceutical enterprises on the 2026 China Brand Value Evaluation List, with a brand strength score of 875 and a calculated brand value of RMB 2.019 billion (approximately USD 280 million). The announcement was made at the “2026 China Brand Value Evaluation Information Release” event held in Deqing, Zhejiang Province, co-organized by the China Brand Construction Promotion Association and the Xinhua News Agency Brand Office, and hosted by China Brand Magazine.
The China Brand Value Evaluation is a nationally recognized, standardized assessment framework aligned with ISO 20671:2019 and relevant Chinese national standards. It evaluates enterprises across five core dimensions: financial performance, intangible assets, quality management, service capability, and innovation capacity—applying principles of scientific rigor, impartiality, transparency, and broad recognition. As a key initiative supporting China’s strategic shift from “Made in China” to “Branded in China,” the evaluation serves as both a benchmark for corporate brand development and a holistic indicator of long-term competitiveness and sustainable growth.
Zuoli Pharmaceutical’s inclusion reflects three decades of focused expertise in medicinal fungal therapeutics. Its flagship product, Wuling Capsules—a patented traditional Chinese medicine (TCM) derived from the fermented mycelium of Ophiocordyceps unilateralis—has established itself as a market leader in the sedative-anxiolytic category. Supported by robust clinical evidence and consistent patient-reported outcomes, the product has repeatedly been named a “Household Essential Medicine” by industry authorities. Quality assurance remains foundational: the company maintains an integrated, end-to-end quality control system spanning raw material sourcing, solid-state fermentation, extraction, formulation, and stability testing—all compliant with Good Manufacturing Practice (GMP) standards.
Innovation is embedded in Zuoli’s core R&D strategy. By pioneering industrial-scale submerged and solid-state fermentation technologies, the company has successfully replaced wild harvesting of the rare fungus Ophiocordyceps unilateralis—a practice historically linked to ecological degradation—with sustainable, controlled bioproduction. To date, Zuoli holds 15 invention patents related to fungal cultivation, bioactive compound isolation, and formulation optimization. All its major therapeutic products are classified as national patent-intensive products under China’s Intellectual Property Administration criteria.
On the service and social responsibility front, Zuoli launched the “Lingdong China” (Agile China) public health initiative in 2024 in partnership with the China Population Welfare Foundation. Focused on early detection and psychosocial support for age-related cognitive decline, the program deployed AI-assisted digital cognitive screening tools across 185 cities nationwide, reaching over one million users. This effort operationalizes the company’s mission: “Supporting human health and advancing China’s pharmaceutical industry.”
Brand equity has also matured significantly: “Zuoli” is now widely recognized as a trusted name in integrative TCM approaches to mental and physical wellness—particularly in the emerging field of psychosomatic medicine. Looking ahead, the company will advance its “One Core, Two Wings” strategic framework—centered on medicinal fungal fermentation technology, with complementary expansion into diversified product portfolios and deepened vertical integration across the supply chain. With renewed momentum from this national brand recognition, Zuoli aims to strengthen its position as a leader in China’s medicinal fungal pharmaceutical sector—and contribute meaningfully to global health through scientifically validated, sustainably produced, and culturally grounded therapies.